文献速递重症综合管理与镇静镇痛复苏、休克与脓毒症呼吸衰竭与机械通气

氢化可的松对重型COVID-19患者死亡率和器官支持的影响:REMAP-CAP COVID-19皮质激素领域随机临床试验

Effect of Hydrocortisone on Mortality and Organ Support in Patients With Severe COVID-19: The REMAP-CAP COVID-19 Corticosteroid Domain Randomized Clinical Trial.
PubMed 文献 · JAMA · 2020-01-01
一句话结论在重型COVID-19患者中,固定7天氢化可的松方案与休克依赖方案相比无氢化可的松,分别有93%和80%的概率在21天内改善无器官支持天数的优势比,但试验提前终止且未达到预设统计学优效标准,无法得出确定性结论。

REMAP-CAP适应性平台试验在8个国家121个中心纳入614例成人疑似或确诊COVID-19患者,入住ICU接受呼吸或心血管器官支持后随机分组;其中403例随机进入皮质激素领域,排除19例撤回知情同意后,384例分为固定剂量氢化可的松组(n=137)、休克依赖组(n=146)和无氢化可的松组(n=101)。固定剂量组接受静脉氢化可的松50mg或100mg每6小时一次,疗程7天;休克依赖组在临床出现休克时给予50mg每6小时一次;无氢化可的松组为对照。主要终点为21天内无器官支持天数(死亡记为-1天)。固定剂量组与无氢化可的松组比较,校正优势比中位数1.43(95%可信区间0.91-2.27),贝叶斯优效概率93%;休克依赖组与无氢化可的松组比较,校正优势比中位数1.22(95%可信区间0.76-1.94),贝叶斯优效概率80%。三组严重不良事件分别报告4例(3%)、5例(3%)和1例(1%)。试验因另一试验结果公布而提前终止,无治疗策略达到预设统计学优效标准,无法得出确定性结论。

要点

  • 固定7天氢化可的松方案(静脉50mg或100mg每6小时一次)与无氢化可的松相比,21天内无器官支持天数改善的校正优势比中位数1.43(95%可信区间0.91-2.27),贝叶斯优效概率93%。
  • 休克依赖氢化可的松方案(临床出现休克时静脉50mg每6小时一次)与无氢化可的松相比,校正优势比中位数1.22(95%可信区间0.76-1.94),贝叶斯优效概率80%。
  • 三组中位无器官支持天数均为0天(固定剂量组IQR -1至15,休克依赖组IQR -1至13,无氢化可的松组IQR -1至11)。
  • 三组死亡率分别为30%、26%和33%,存活者中位无器官支持天数分别为11.5天、9.5天和6天。
  • 试验提前终止且无治疗策略达到预设统计学优效标准(优效阈值>99%),无法得出确定性结论。

适用人群与场景

  • 成人(平均年龄60岁,女性29%)疑似或确诊COVID-19患者,入住ICU接受呼吸或心血管器官支持后随机分组。
  • 纳入8个国家121个中心,2020年3月9日至6月17日入组,随访至2020年8月12日。

诊断标准与关键阈值

  • 重型COVID-19:疑似或确诊COVID-19并入住ICU接受呼吸或心血管器官支持。
  • 优效性判定标准:优势比大于1的后验概率>99%。

处置流程与药物剂量

  • 固定剂量组:静脉氢化可的松50mg或100mg每6小时一次,疗程7天。
  • 休克依赖组:临床出现休克时静脉氢化可的松50mg每6小时一次。
  • 对照组:不使用氢化可的松。

研究设计与关键结果

  • REMAP-CAP适应性平台试验,8个国家121个中心,614例成人疑似或确诊COVID-19患者入组,其中403例随机进入皮质激素领域,排除19例撤回知情同意后384例纳入分析(固定剂量组n=137,休克依赖组n=146,无氢化可的松组n=101),379例(99%)完成研究。
  • 三组平均年龄59.5至60.4岁,男性占70.6%至71.5%,平均体重指数29.7至30.9,接受机械通气者占50.0%至63.5%。
  • 主要终点21天内无器官支持天数:固定剂量组中位0天(IQR -1至15),休克依赖组中位0天(IQR -1至13),无氢化可的松组中位0天(IQR -1至11)。
  • 固定剂量组与无氢化可的松组比较:校正优势比中位数1.43(95%可信区间0.91-2.27),贝叶斯优效概率93%;休克依赖组与无氢化可的松组比较:校正优势比中位数1.22(95%可信区间0.76-1.94),贝叶斯优效概率80%。
  • 死亡率:固定剂量组30%,休克依赖组26%,无氢化可的松组33%;存活者中位无器官支持天数分别为11.5天、9.5天和6天。
  • 严重不良事件:固定剂量组4例(3%),休克依赖组5例(3%),无氢化可的松组1例(1%)。

证据类型、等级与局限

  • 证据类型:适应性平台随机临床试验(REMAP-CAP)。
  • 试验提前终止且无治疗策略达到预设统计学优效标准(优效阈值>99%),无法得出确定性结论。

对床旁实践的改变

  • 作者结论:在重型COVID-19患者中,7天固定剂量氢化可的松方案或休克依赖氢化可的松方案与无氢化可的松相比,21天内无器官支持天数改善的优势比优效概率分别为93%和80%,但试验提前终止且未达到预设统计学优效标准,无法得出确定性结论。

指南或共识出处

  • REMAP-CAP COVID-19皮质激素领域随机临床试验(NCT02735707),发表于JAMA。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: Evidence regarding corticosteroid use for severe coronavirus disease 2019 (COVID-19) is limited.

OBJECTIVE: To determine whether hydrocortisone improves outcome for patients with severe COVID-19.

DESIGN, SETTING, AND PARTICIPANTS: An ongoing adaptive platform trial testing multiple interventions within multiple therapeutic domains, for example, antiviral agents, corticosteroids, or immunoglobulin. Between March 9 and June 17, 2020, 614 adult patients with suspected or confirmed COVID-19 were enrolled and randomized within at least 1 domain following admission to an intensive care unit (ICU) for respiratory or cardiovascular organ support at 121 sites in 8 countries. Of these, 403 were randomized to open-label interventions within the corticosteroid domain. The domain was halted after results from another trial were released. Follow-up ended August 12, 2020.

INTERVENTIONS: The corticosteroid domain randomized participants to a fixed 7-day course of intravenous hydrocortisone (50 mg or 100 mg every 6 hours) (n = 143), a shock-dependent course (50 mg every 6 hours when shock was clinically evident) (n = 152), or no hydrocortisone (n = 108).

MAIN OUTCOMES AND MEASURES: The primary end point was organ support-free days (days alive and free of ICU-based respiratory or cardiovascular support) within 21 days, where patients who died were assigned -1 day. The primary analysis was a bayesian cumulative logistic model that included all patients enrolled with severe COVID-19, adjusting for age, sex, site, region, time, assignment to interventions within other domains, and domain and intervention eligibility. Superiority was defined as the posterior probability of an odds ratio greater than 1 (threshold for trial conclusion of superiority >99%).

RESULTS: After excluding 19 participants who withdrew consent, there were 384 patients (mean age, 60 years; 29% female) randomized to the fixed-dose (n = 137), shock-dependent (n = 146), and no (n = 101) hydrocortisone groups; 379 (99%) completed the study and were included in the analysis. The mean age for the 3 groups ranged between 59.5 and 60.4 years; most patients were male (range, 70.6%-71.5%); mean body mass index ranged between 29.7 and 30.9; and patients receiving mechanical ventilation ranged between 50.0% and 63.5%. For the fixed-dose, shock-dependent, and no hydrocortisone groups, respectively, the median organ support-free days were 0 (IQR, -1 to 15), 0 (IQR, -1 to 13), and 0 (-1 to 11) days (composed of 30%, 26%, and 33% mortality rates and 11.5, 9.5, and 6 median organ support-free days among survivors). The median adjusted odds ratio and bayesian probability of superiority were 1.43 (95% credible interval, 0.91-2.27) and 93% for fixed-dose hydrocortisone, respectively, and were 1.22 (95% credible interval, 0.76-1.94) and 80% for shock-dependent hydrocortisone compared with no hydrocortisone. Serious adverse events were reported in 4 (3%), 5 (3%), and 1 (1%) patients in the fixed-dose, shock-dependent, and no hydrocortisone groups, respectively.

CONCLUSIONS AND RELEVANCE: Among patients with severe COVID-19, treatment with a 7-day fixed-dose course of hydrocortisone or shock-dependent dosing of hydrocortisone, compared with no hydrocortisone, resulted in 93% and 80% probabilities of superiority with regard to the odds of improvement in organ support-free days within 21 days. However, the trial was stopped early and no treatment strategy met prespecified criteria for statistical superiority, precluding definitive conclusions.

TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02735707.

来源:JAMA,查看原文。版权归原作者所有。

参考来源

  1. Angus DC, Derde L, Al-Beidh F, et al. Effect of Hydrocortisone on Mortality and Organ Support in Patients With Severe COVID-19: The REMAP-CAP COVID-19 Corticosteroid Domain Randomized Clinical Trial. JAMA. 2020. PMID: 32876697. doi:10.1001/jama.2020.17022

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。